曲美他嗪对糖尿病心肌病患者血清hs-CRP、NT-proBNP及Tei指数的影响  

Effect of trimetazidine on serum hs-CRP, NT-proBNP and Tei index in the patients with diabetic cardiomyopathy

作　　者：王春雷[1] 唐杨[1] 刘林琼 向姝[2] 

机构地区：[1]重庆市巴南区人民医院心血管内科,重庆401320 [2]重庆市巴南区人民医院内分泌科,重庆401320

出　　处：《海南医学》2018年第5期609-611,共3页Hainan Medical Journal

基　　金：重庆市巴南区科委科研项目(编号:2014-6)

摘　　要：目的探讨曲美他嗪对糖尿病心肌病(DCM)患者血清超敏C反应蛋白(hs-CRP)、氨基末端脑钠肽前体(NT-pro BNP)及Tei指数的影响。方法选取2015年1月至2017年1月收住重庆市巴南区人民医院血管内科和内分泌科的90例DCM患者为研究对象,按随机数表法分为对照组和观察组各45例,对照组予常规综合治疗,观察组在常规综合治疗基础上加用曲美他嗪片口服治疗,疗程均为10周。比较两组患者入院时及治疗10周后hsCRP、NT-pro BNP水平及Tei指数的差异。结果两组患者入院后的hs-CRP、NT-pro BNP水平及Tei指数比较差异均无统计学意义(P>0.05);治疗10周后,观察组和对照组患者的hs-CRP[(5.2±1.2)mg/L vs(6.5±1.7)mg/L]、NTpro BNP[(231.65±71.39)pg/L vs(314.31±85.21)pg/L]和Tei指数[(0.502±0.021)vs(0.541±0.016)]比较,观察组均较对照组明显下降,差异均有统计学意义(P<0.05);两组患者治疗期间均未发现严重的药物相关不良事件。结论曲美他嗪能够显著降低DCM患者血清hs-CRP、NT-pro BNP水平,改善患者Tei指数,提高临床疗效。Objective To investigate the effects of trimetazidine on diabetic cardiomyopathy （DCM） pa-tients＇ hypersensitive C-reactive protein （hs-CRP）, N-terminal pro-natriuretic peptide （NT-proBNP） and Tei index.Methods A total of 90 DCM patients, who admitted to Department of Cardiology and Endocrinology in ChongqingBanan District People＇s Hospital from Jan. 2015 to Jan. 2017, were selected and randomly divided into the observationgroup and control group according to the random number table method, with 45 cases in each group. The control groupwas given conventional treatment, and the observation group was treated with trimetazidine additionally. Both groupswere treated continuously for 10 weeks. The serum hs-CRP, NT-proBNP concentration and Tei index of the two groupsbefore treatment and ten weeks after treatment were compared. Results At admission, there were no significant differ-ences between the two groups in patients＇ plasma values of hs-CRP, NT-proBNP and Tei index （P〉0.05）. After ten weeksof treatment, the serum hs-CRP, NT-proBNP concentration and Tei index in the observation group were （5.2±1.2） mg/L,（231.65±71.39） pg/L, （0.502±0.021）, respectively, which were significantly lower than corresponding （6.5±1.7） mg/L,（314.31±85.21） pg/L, （0.541±0.016） in the control group （P〈0.05）. No severe side effect was found in both groups dur-ing therapy. Conclusion Trimetazidine can significantly decrease the levels of serum hs-CRP and NT-proBNP, improveTei index, and increase the clinical efficacy.

关 键 词：糖尿病心肌病 曲美他嗪 TEI指数 疗效 

分 类 号：R587.2[医药卫生—内分泌]